Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.43 |
| ▸ | HTR2C | P28335 | 5/20 | 0.41 |
| ▸ | HTR2B | P41595 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | LATS1 | O95835 | 1/20 | 0.36 |
| ▸ | SPAST | Q9UBP0 | 1/20 | 0.36 |
| ▸ | KHK | P50053 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28966630 | 1.00 | ROCK2 (0.43) | ROCK2HTR2CHTR2BCYP1A2CYP3A4 | |
| SCHEMBL24962983 | 1.00 | ROCK2 (0.43) | ROCK2HTR2CHTR2BCYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL28966586 | 0.99 | ROCK2 (0.42) | ROCK2HTR2CHTR2BCYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL28966581 | 0.99 | ROCK2 (0.42) | ROCK2HTR2CHTR2BCYP1A2CYP3A4 | |
| SCHEMBL17413 | 0.86 | ROCK2 (0.40) | ROCK2HTR2CHTR2BCYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL17409 | 0.85 | ROCK2 (0.39) | ROCK2HTR2CHTR2BCYP1A2CYP3A4 | |
| SCHEMBL17104 | 0.85 | ROCK2 (0.39) | ROCK2HTR2CHTR2BCYP1A2CYP3A4 | |
| SCHEMBL12089177 | 0.84 | ROCK2 (0.40) | ROCK2HTR2CHTR2BCYP1A2CYP3A4 | |
| SCHEMBL31713305 | 0.84 | ROCK2 (0.40) | ROCK2HTR2CHTR2BCYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL16587 | 0.84 | ROCK2 (0.39) | ROCK2HTR2CHTR2BCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100410-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4644385-A1 | TIPARP INHIBITOR COMPOUNDS | AbbVie Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250333394-A1 | Tiparp Inhibitor Compounds | ABBVIE INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023001247-A1 | PYRIDAZINONE COMPOUND | 南京明德新药研发有限公司 | 2023-01-26 | — | — | WO | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333394-A1 | Tiparp Inhibitor Compounds | TIPARP, TIPRL, TPP1 | ROCK2 1310/4885HTR2C 4157/4885HTR2B 4727/4885 |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | ROCK2 2599/4885HTR2C 235/4885HTR2B 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.